DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53-deficient pancreatic cancer cells

WEI JING1,2, NA SONG3, YUNPENG LIU3, XIUJUAN QU3, KEZUO HOU3, Xianghong Yang2 and Xiaofang Che3

Departments of 1Oncology and 2Pathology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004; 3Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China

Received December 17, 2016; Accepted August 1, 2017

DOI: 10.3892/mmr.2017.7923

Abstract. The aberrant expression of DNA methyltransferases (DNMTs) has been considered to be associated with pancreatic carcinogenesis and progression. DNMT3a is widely involved in cell proliferation and cell cycle progression in pancreatic ductal adenocarcinoma (PDAC) cells. However, its regulation of chemosensitivity to gemcitabine (GEM) and oxaliplatin (OXA) in p53-deficient PDAC remains unclear. In the present study, the effect and mechanisms of DNMT3a on GEM and OXA chemosensitivity in p53-deficient PDAC cells were investigated using MTT assay, cell cycle analysis, apoptosis analysis and western blotting. The treatment of GEM and OXA induced S phase arrest by DNA damage, and enhanced the activation of the AKT signaling pathway in Panc-1 cells. Downregulation of DNMT3a increased the chemosensitivity to both GEM and OXA in Panc-1 cells. DNMT3a depletion distinctly abolished S phase arrest induced by GEM and OXA. Further research demonstrated that activation inhibition of CHK1 and AKT, as well as an increase in apoptosis, were involved in DNMT3a-mediated chemosensitivity to GEM and OXA. Taken together, these data demonstrated that DNMT3a serves a crucial role in the regulation of chemosensitivity to GEM and OXA, and suggests a promising therapeutic target for p53-deficient PDAC.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) with its highly lethal malignancy affected >79,400 people in China in 2015 (1). While it is a rapidly invasive, metastatic tumor, nearly 80% of PDAC patients are unresectable at diagnosis due to advanced stages or distant metastasis. The prognosis of PDAC has not been significantly improved, despite advances in comprehensive treatment (2). The overall 5-year survival rate for PDAC is still ~5% (1). Comprehensive treatment, particularly chemotherapy, is the main strategy for most PDAC patients. However, the effect of chemotherapy is still limited, for both monotherapy and polytherapy.

A variety of molecular and genetic changes exist in the development of PDAC (3,4). Aberrant DNA hypermethylation is considered to be associated with tumorigenesis in human pancreatic tumors (5). DNA methyltransferases (DNMTs), the key cellular enzymes in epigenetic modifications, serve a major role in transferring the methyl group to cytosine in CpG islands, and are comprised of the three families of DNMT1, DNMT3 and DNMT3b.

DNMT1 is responsible for the maintenance of the DNA methylation pattern during DNA replication, whereas DNMT3 functions as a de novo methyltransferase acting on unmethylated and hemimethylated DNA. DNMTs restrain tumor suppressor gene transcription by promoting methylation of CpG islands in the promoter, thus contributing to the occurrence and development of the tumor. Previous studies have demonstrated that DNMT1 and DNMT3a are overexpressed in a variety of human tumors, including gastric cancer and pancreatic cancer (6,7), and overexpression of DNMT1 and DNMT3a is inversely associated with the prognosis of PDAC (8,9). Methylation-mediated tumor suppressor gene silencing, which does not involve altering the DNA base sequence, can be reversed by pharmacological or chemical intervention. Therefore, DNMTs have been considered as potential anti-cancer therapeutic targets (10). Inhibition of DNMT1 had synergic effects on the cytotoxicity induced by
chemotherapeutic drugs in multiple tumor models, including pancreatic cancer (11,12). However, the role of DNMT3a in chemosensitivity remained elusive in PDAC.

Gemcitabine (GEM) and oxaliplatin (OXA) are DNA damage agents, which have been applied in the treatment of PDAC extensively. GEM and 5-fluorouracil (5-FU) have been used as the main chemotherapeutic regimens for PDAC in the last two decades. Recently, clinical studies demonstrated that combined GEM and erlotinib or albumin-bound paclitaxel therapy improved overall survival by <2 months in metastatic PDAC (13,14). Furthermore, another combined chemotherapeutic regimen of FOLFIRINOX, including OXA, irinotecan, 5-FU and leucovorin, improved the median overall survival for 4.3 months compared with GEM monotherapy as a first-line therapy for patients with metastatic PDAC (15). Therefore, the objective response of GEM and OXA still remains limited (16). Thus, there is an urgent need to improve chemotherapeutic efficacy in PDAC.

DNA damage in cancer cells caused by DNA damage agents raises the activation of cellular responses, including p53 and serine-protein kinase ATM-cell cycle checkpoint kinase (CHK)2 and serine/threonine-protein kinase ATR (ATR)-CHK1 pathways, which cause the DNA damage response. It induces cell cycle arrest to repair DNA damage, evading the cytotoxicity of chemotherapeutic agents. P53-deficient cancer cells, unlike normal cells, rely mainly on phosphorylation of S or G2 CHK1, which induces S phase arrest in response to DNA damage, instead of p53 (17). An accumulation of phosphorylated CHK1 induced by GEM treatment leads to S-phase arrest in Panc-1 cells, which prevents premature mitotic entry, and CHK1 depletion enhances GEM-mediated cytotoxicity and radiosensitization (18). Inhibition of CHK1 potentiates the cytotoxicity of irinotecan in triple-negative breast cancer (19), and overcomes the cisplatin resistance in head and neck cancer cells with loss of functional p53 (20). Therefore, CHK1 is regarded as a potential target in p53-deficient cancer, such as PDAC, with nearly 50% patients being p53-deficient. A previous study demonstrated DNMT3a mediates the cell cycle progression in PDAC cells. However, whether DNMTs affect the activation of CHK1 is unknown.

Previous research demonstrated DNMT1 and DNMT3a are widely expressed in PDAC, mediating the proliferation and cell cycle progression in PDAC cells. However, in our previous work, it was found that downregulation of DNMT3a had synergistic effects with GEM or OXA in p53-deficient PDAC cells, which was not detected in DNMT1 inhibition (data not published). The present study investigated the regulation of DNMT3a on chemosensitivity to GEM and OXA, and the potential mechanisms in p53-deficient PDAC cells. Additionally, the role of DNMT3a on CHK1 activity, which contributes to GEM and OXA sensitivity, was assessed.

Materials and methods

Cell culture and reagents. The Panc-1 p53-deficient pancreatic cancer cells were obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). Panc-1 cells were cultured in RPMI1640 medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS), and 100 U/ml penicillin-streptomycin at 37°C and 5% CO2. GEM was obtained from Eli Lilly, Inc. (Indianapolis, IN, USA). Oxaliplatin was purchased from Sanofi-Aventis, Inc. (Paris, France). Antibodies against CHK1 (cat. no. 2360S), phosphorylated (p)-CHK1 (Ser345; cat. no. 2348S), poly[ADP-ribose] polymerase (PARP; cat. no. 9542L), protein kinase B (AKT; cat. no. 9272S), p-AKT (Ser473; cat. no. 9271L), p-extracellular signal-regulated kinase (ERK1/2) (Thr202/Tyr204; cat. no. 4370S), Caspase-3 (cat. no. 9663S) and γ-histone H2AX (γ-H2AX; cat. no. 9718S) were obtained from Cell Signaling Technology, Inc. (Danvers, MA, USA). Anti-DNMT3a (cat. no. sc-20703), anti-GAPDH (cat. no. sc-25778), anti-ERK (cat. no. sc-514302), and secondary goat anti-rabbit (cat. no. sc-2007) and goat anti-mouse antibodies (cat. no. sc-2039) were obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

Transient transfection. Small interfering RNA (siRNA) of DNMT3a from Shanghai Gemma Pharmaceutical Technology, Co., Ltd. (Shanghai, China) was used: 5'-GGCGUCACAGA AGCAUATTTAUGUCUCUGUGACGTTT-3'. The negative-control siRNA sequence was 5'-AATTTCCGGAC GTTGCAGCTG-3'. Panc-1 cells were transfected with DNMT3a siRNA, negative-control siRNA and Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol, and the transfection medium was replaced 4-6 h after transfection.

MTT assay. Panc-1 cells were seeded at 6x104 cells per well into 96-well plates with three replicate wells for each condition. Cells treated with GEM and OXA were cultured in 96-well plates for 48 h. A total of 24 h after transfection, GEM and OXA were added to each corresponding well to continue culturing for 48 h, with final concentration of 1 and 5 μM, respectively. Cells were then harvested for MTT assay. MTT (20 μl; 5 mg/ml) reagent was added to each well, and the incubation continued for 4 h at 37°C. After removal of the supernatant, dimethyl sulfoxide (DMSO; 200 μl/well) was added to dissolve the formazan crystals. The optical density was measured at 570 nm with a microplate reader (Model 550, Bio-Rad Laboratories, Inc., Hercules, CA, USA). All experiments were repeated three times.

Western blot analysis. The cells were washed with ice-cold PBS twice, lysed in lysis buffer (1% Triton X-100, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 10 mM EDTA, 100 mM NaF, 1 mM NaVO4, 1 mM PMSF and 2 μg/ml aprotinin) and quantified with the Coomassie brilliant blue G-250 method (Shanghai Maikun Chemical Co., Ltd, Shanghai, China). The supernatant was diluted in 3X SDS loading buffer and then boiled for 5 min. Proteins (20 μg) were separated on 8-12% gels by SDS-PAGE, then transferred onto a polyvinylidene difluoride membrane. The membranes were blocked with 5% skimmed milk in TBS with Tween 20 (TBST) buffer (10 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.1% Tween 20) at room temperature for 1 h. The membranes were incubated overnight with the antibodies CHK1 (1:1,000), p-CHK1 (1:500), PARP (1:1,000), AKT (1:1,000), p-AKT (1:500), p-ERK1/2 (1:500), Caspase-3 (1:1,000), γ-H2AX (1:1,000), DNMT3a (1:1,000), GAPDH (1:1,000) and ERK1/2 (1:500) at 4°C. Following
washing with TTBS buffer three times, the membrane was incubated with secondary goat anti-rabbit (1:1,000) and goat anti-mouse (1:500) antibodies for 30 min at room temperature. Finally, the protein bands were ultimately visualized with a MicroChemi 4.2 Gel Capture version 6.12 (DNR Bio-Imaging Systems, Ltd., Neve Yamin, Israel).

Cell cycle analysis. Panc-1 cells were treated with GEM (5 µM) and OXA (5 µM) for 12 and 24 h, respectively. In the meantime, the cells were transfected with negative-control siRNA or DNMT3a siRNA for 48 h. After transfection, GEM was added for 12 h with a final concentration of 5 µM, and OXA was added for 24 h with a final concentration of 5 µM. Cells were washed with cold PBS twice, and fixed with ice-cold 70% ethanol overnight at 4˚C and then incubated with 100 µg/ml RNase A in PBS for 30 min at 37˚C. Subsequently, cells were stained with propidium iodide (PI; 5 mg/ml) for another 30 min at 37˚C away from light. A BD Accuri C6 FACScanflow cytometer (BD Biosciences, Franklin Lakes, NJ, USA) and ModFit LT software version 3.3 (modfit-lt.software.informer.com/download; Verity Software House, Inc., Topsham, ME, USA) were used to analyze cell cycle distribution. All experiments were repeated three times.

Apoptosis analysis. Panc-1 cells were seeded at 3x10^5 cells per well into 6-well plates. Cells were transfected with negative-control siRNA, DNMT3a siRNA using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. A total of 24 h after transfection, GEM and OXA were added for 48 h with a final concentration of 5 µM. Subsequently, cells were harvested and resuspended in binding buffer containing Annexin V-FITC and PI according to the instructions of the Annexin V-FITC/PI Apoptosis Detection kit (Invitrogen; Thermo Fisher Scientific, Inc.). The percentage of apoptosis was analyzed by flow cytometry. For each group, the process was repeated three times.

Statistical analysis. All experiments were repeated at least three times. All values are expressed as the mean ± standard error. Differences between the multiple groups were evaluated by one-way analysis of variance with a post-hoc LSD test, and differences between the two groups were evaluated by Student's t-test (two-tailed). SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. P<0.05 was considered to indicate a statistically significant difference.

Results
DNMT3a downregulation increases GEM and OXA sensitivity of p53-deficient PDAC cells. First, GEM and OXA sensitivity was examined in Panc-1 cells. The results demonstrated that cell viability was inhibited by GEM and OXA in a dose-dependent manner in 48 h. Panc-1 cells treated with GEM had significantly greater viability than cells treated with OXA (Fig. 1A). The cell viability rates of Panc-1 cells treated with 5 µM GEM for 48 h was 82.13±1.93%, (P=0.007), and for cells treated with 5 µM OXA was 63.84±14.49% (P=0.001). To identify the role of DNMT3a in regulating chemosensitivity, siRNA was used to knockdown the expression of DNMT3a in Panc-1 cells, and the efficiency of DNMT3a suppression by siRNA was confirmed by western blotting (Fig. 1B). Subsequently, the effects of DNMT3a downregulation on the sensitivity of pancreatic cancer cells to GEM and OXA was examined by MTT assay. The results demonstrated that the downregulation of DNMT3a increased the drug-sensitivity of Panc-1 to both GEM and OXA (Fig. 1C; Table I). These data suggested that DNMT3a downregulation increased sensitivity of Panc-1 cells to GEM and OXA.
GEM and OXA induce the activation of AKT and CHK1 in Panc-1 cells. To investigate the effect of GEM and OXA on cell proliferation and DNA damage, western blot analysis and flow cytometry were performed to identify the expression of associated proteins and the cell cycle. p-AKT and p-ERK were gradually elevated by GEM and OXA in Panc-1 cells, which reached a peak at 6 h following GEM or OXA treatment (Fig. 2A). Flow cytometry revealed that the accumulation in S phase cells was increased with following treatment of GEM or OXA for 12 and 24 h, respectively (Fig. 2B). The percentage of S phase cells increased from 39.19±5.43 to 49.27a±3.99% following GEM treatment, and 41.48±2.43 to 51.81±3.28% following OXA treatment (Fig. 2C). Furthermore, γ-H2AX was activated in a time-dependent manner in Panc-1 cells treated with GEM and OXA. In addition, a significant phosphorylation of CHK1 was observed after drug treatment for 6 h (Fig. 2D). Taken together, these data suggested that GEM and OXA, as DNA damage agents, not only induced cell cycle arrest, but also stimulated the cell proliferation signal pathway, which may cause limited inhibition of GEM and OXA in Panc-1 cells.

DNMT3a downregulation promotes cell apoptosis induced by GEM and OXA. The cytotoxicity of GEM and OXA not only inhibited proliferative signal and cell cycle arrest, but also induced apoptosis in cancer cells. Annexin V-FITC/PI and western blot analysis were performed to elucidate cell apoptosis. Annexin V-FITC/PI demonstrated that DNMT3a downregulation combined with GEM or OXA increased cell apoptosis (GEM + NC vs. GEM + siDNMT3a: 7.97±2.11% vs. 19.87±3.23%, P<0.001; OXA + NC vs. OXA + siDNMT3a: 4.4±1.65% vs. 16.57±2.44%, P<0.001; Fig. 3A and B). Similarly, dual inhibition with DNMT3a siRNA and drug treatment distinctly induced cleavage of PARP and caspase-3 compared to single agent treatment (Fig. 3C). Thus, DNMT3a downregulation increased apoptosis in GEM and OXA-treated Panc-1 cells.

DNMT3a downregulation abrogates the activation of AKT and CHK1 and cell cycle arrest induced by GEM and OXA. Next, the change of AKT and ERK signaling and cell cycle when DNMT3a was downregulated was investigated. The results demonstrated that downregulation of DNMT3a could significantly inhibit the AKT activation induced by GEM and OXA at 6 h, while no obvious change of p-ERK was observed in Panc-1 cells (Fig. 4A). Additionally, downregulation of DNMT3a distinctly abolished the blockage of S phase arrest induced by GEM and OXA at 12 and 24 h, and enhanced G1/G0 phase arrest (Fig. 4B). Downregulation of DNMT3a restored the S phase arrest response to GEM and OXA in Panc-1 cells (GEM + NC vs. GEM + siDNMT3a: 5.49±6.37% vs. 17.88±4.25%, P=0.001; OXA + NC vs. OXA + siDNMT3a: 45.35±6.15% vs. 24.18±4.93%, P<0.001), and raised G1/G0 percentage (GEM + NC vs. GEM + siDNMT3a: 64.51±6.37% vs. 82.12±4.25%, P=0.003; OXA + NC vs. OXA + siDNMT3a: 46.35±6.91% vs. 75.26±4.00%, P<0.001; Fig. 4C). Furthermore, p-CHK1 expression induced by GEM and OXA at 6 h apparently decreased after DNMT3a downregulation in Panc-1 cells (Fig. 4D). These results indicated that DNMT3a downregulation enhanced the sensitivity of GEM and OXA in Panc-1 cells by disrupting the activation of AKT, CHK1 and S phase arrest.

Discussion

Aberrant methylation has been considered to be involved in pancreatic carcinogenesis and progression. Inhibition of the function of DNMTs has been proven to be a potential target for improving survival and reinforcing therapeutic effect (5,9,10). The present study reported that the cytotoxicity of GEM and OXA was significantly enhanced in DNMT3a knockdown Panc-1 cells. The underlying mechanisms suggested DNMT3a downregulation inhibited the activation of CHK1 and decreased the S phase fraction in Panc-1 cells after drug administration. On the other hand, DNMT3a downregulation also suppressed AKT activation to inhibit the responsiveness to DNA damage, and increase cell apoptosis caused by chemotherapeutic drugs. These data suggested that DNMT3a served an important role in the chemotherapy sensitivity of p53-deficient PDAC cells.

CHK1 is the most important serine/threonine kinase in the cell cycle checkpoint during DNA damage responses. It is overexpressed in a variety of human tumors, especially in breast, cervical and gastric carcinomas (21-23). The activation of the ATR-CHK1 pathway in response to DNA damage leads to cell cycle arrest for DNA repair during the application of radiotherapy or anti-cancer therapy agents (24). Accordingly, CHK1 inhibition potentiates the sensitivity of multiple DNA damage chemotherapy agents by restraining the DNA damage response, especially antimitobolites, notably GEM, which is widely used in various of solid tumors (25,26). In addition, decreased expression of CHK1 leads to sensitization of mesothelioma cells to platinum, and hepatocellular carcinoma cells to cisplatin (27,28). In p53-deficient cells, CHK1 dominates in cell cycle regulation after DNA damage instead of G1/G0 checkpoint p53. Therefore, p53-deficient cancer cells are considered to be more sensitive to therapeutic strategies that combine DNA damaging agents with CHK1 inhibitors (29). Encouraging
Figure 2. GEM and OXA induces activation of AKT and CHK1 in Panc-1 cells. (A) The expression of p-AKT, AKT, p-ERK and ERK in Panc-1 cells treated with GEM (5 µM) and OXA (5 µM) for 0, 1, 6, 24 h was analyzed by western blot. (B) The cell cycle was detected by flow cytometry in Panc-1 cells after GEM (5 µM) and OXA (5 µM) treatment for 12 and 24 h and (C) percentage of cells in S phase. (D) Cells were treated with GEM (5 µM) and OXA (5 µM) for 0, 1, 6 and 24 h. Expression of γ-H2AX, p-CHK1 and CHK1 were determined by western blot analysis. Data are presented as the mean ± standard deviation. *P<0.05.

Con, control; GEM, gemcitabine; OXA, oxaliplatin; p, phosphorylated; AKT, protein kinase B; γ-H2AX, γ-histone H2AX; ERK, extracellular signal-regulated kinase; CHK1, cell cycle checkpoint kinase 1.
results were obtained with combination of demethylating agents and classic anticancer chemotherapeutics in colorectal cancer. DNMTs inhibitors could potentiate the inhibitory effects of OXA in colorectal cancer cells, while activation of CHK1 respond to DNA damage response varied in different DNMT inhibitors (30). The role executed by different members of the DNMT family is still unidentified and needs to be evaluated (30). In the present study, it was demonstrated that p-CHK1 and γ-H2AX expression levels were elevated in p53-deficient Panc-1 cells following DNA damage caused by GEM and OXA, accompanied by cell accumulation in S phase. Inhibition of DNMT3a restored the S phase fraction and CHK1 activation, arrested cells in G$_0$/G$_1$ phase and increased response to chemotherapy treatment. These results highlighted that DNMT3a downregulation enhanced the sensitivity of GEM and OXA in p53-deficient Panc-1 cells by disrupting the activation of CHK1. However, there was no methylation loci in the promoter of CHK1, and molecules directly regulated by DNMT3a through epigenetic regulation, which could modify the phosphorylation of CHK1, were not investigated. Thus, DNMT3a may regulate CHK1 activation via an indirect effect in Panc-1 cells, and further study is needed to elucidate the underlying mechanisms.

AKT serves a critical role in regulating cellular processes in cancer cells, including cell proliferation, anti-apoptosis, migration and drug resistance. An excessive activation of p-AKT may induce multidrug resistance in cancer (31). In pancreatic cancer, abnormal AKT activation is an analogous mechanism affecting chemoresistance to GEM. The combination with an AKT inhibitor and GEM synergistically inhibited pancreatic cancer cell growth (32). An excessive activation of AKT made a great contribution to OXA resistance in hepatocellular carcinoma (33). In addition, activation of AKT can also be induced by DNA damage. DNA damage caused by cisplatin induces activation of AKT in platinum-resistant ovarian cancer cells, implicating AKT-activation as a resistance mechanism (34). The present study observed that AKT/ERK-mediated pro-survival signaling was markedly activated following treatment with GEM and OXA in Panc-1 cells. However, downregulation of DNMT3a merely decreased the activation of AKT in response to cytotoxic agents, and improved the sensitivity to GEM and OXA. These results revealed that there was a suppression of the proliferation signal as a synergistic therapeutic effect of GEM/OXA and DNMT3a inhibition.

According to previous studies, chemotherapeutic drugs cause anti-tumor effects partly by promoting cell apoptosis. In the present study, the increased cell apoptosis was detected in cells combined with DNMT3a downregulation and GEM/OXA, which was considered to be induced by the effect of irreversible DNA damage and depressing AKT activation. However, further research is needed to discover whether there are other factors leading to apoptosis.

In conclusion, the present study demonstrated that DNMT3a downregulation enhanced the chemotherapeutic toxicity of GEM and OXA by suppressing the phosphorylation
of CHK1 and AKT, inhibiting S phase arrest and promoting apoptosis in Panc-1 cells, suggesting the suppression of DNMT3a sensitized p53-deficient pancreatic cancer to DNA damage chemotherapeutic agents. Therefore, the present study implicated DNMT3a as a promising crucial therapeutic target for p53-deficient PDAC therapy.
Acknowledgements

The present study was supported by Outstanding Scientific Foundation of Shengjing Hospital (grant no. 201210) and the National Natural Science Foundation of China (grant no. 81401938).

References

1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin 66: 115-129, 2016.

2. Sinn M, Bahra M, Denecke T, Travis S, Pelzer U and Riess H: Perioperative treatment options in resectable pancreatic cancer-how to improve long-term survival. World J Gastrointest Oncol 8: 248-257, 2016.

3. Delpu Y, Hanoun N, Laluka H, Sicard F, Selves J, Buscall L, Torrisani J and Cordelier P: Genetic and epigenetic alterations in pancreatic carcinogenesis. Current Genomics 12: 15-24, 2011.

4. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, et al: Pancreatic cancer genomes reveal aberrations in axon guidance mechanisms. Nature 498: 339-344, 2013.

5. Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, Kosuge T and Hirohshi S: Increased DNA methyltransferase 1 (DNMT1) protein expression in preneoplastic conditions and ductal carcinomas of the pancreas. Cancer Sci 96: 403-408, 2005.

6. Yang T, Wei X, Wu Q, Xu Z, Gu D, Jin Y, Shen Y, Huang H, Fan H and Chen J: Clinical significance of the expression of DNA methyltransferase proteins in gastric cancer. Mol Med Rep 4: 1139-1143, 2011.

7. He S, Wang F, Yang L, Guo C, Wan R, Ke A, Xu L, Hu G, Xu Y, Shen J and Wang X: Expression of DNMT1 and DNMT3a are regulated by GLI1 in human pancreatic cancer. PLoS One 6: e27684, 2011.

8. Zhang JJ, Zhu Y, Zhu Y, Wu JL, Liang WB, Zhu R, Xu ZK, Du Q and Miao Y: Association of increased DNA methyltransferase expression with carcinogenesis and poor prognosis in pancreatic ductal adenocarcinoma. Clin Transl Oncol 14: 116-124, 2012.

9. Gao J, Wang L, Xu J, Zheng J, Man X, Wu H, Jin J, Wang K, Xiao H, Li S and Li Z: Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression. J Exp Clin Cancer Res 32: 86, 2013.

10. Ghoshal K and Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 43: 395-422, 2007.

11. Mutze K, Langer R, Schumacher F, Becker K, Ott K, Novotny A, Hafelmeier A, Höfler H and Keller G: DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in pancreatic cancer. Eur J Cancer 47: 1817-1825, 2011.

12. Nagaraju GP, Zhu S, Wen J, Farris AB, Adsay VN, Diaz R, Figer A, Hecht JR, Gallinger S, Becker K, Ott K, Novotny A, Commo F, Saghatchian M, Lazar V, Dessel P, et al: CHK1 as a new therapeutic target in triple-negative breast cancer. Breast 23: 250-258, 2014.

13. Bargiela-Iprarraguirre J, Prado-Marchal L, Fernandez-Fuente M, Gutierrez-Gonzalez A, Moreno-Rubio J, Muñoz-Fernandez M, Sereno M, Sanchez-Prieto R, Perona R and Sanchez-Perez I: CHK1 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 12: 1860-1873, 2013.

14. Algibis L, Goubar A, Scott Y, Vicier C, Lefèbvre C, Alsafadi S, Commo F, Saghatelian M, Lazar V, Dessel P, et al: CHK1 as a new therapeutic target in triple-negative breast cancer. Breast 23: 250-258, 2014.

15. Gohde MA, Scuito MR, Alves MV, Pickering CR, Osman AA, Nesmy DK, Zhao M, Fitzgerald AL, Myers JN and Friedman MJ: CHK1 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 12: 1860-1873, 2013.

16. Figueiredo AK, Lopes AC, Almeida AM, de Andrade M, Lessa ES, Costa HS and de Jesus R: Mutations in ATM, p53, and MDM2 are associated with poor outcome in recurrent cervical carcinoma. Cancer 114: 1529-1535, 2008.

17. Shen J and Wang X: CHK1 targets spleen tyrosine kinase (L) for proteolysis in gastric cancer-how to improve long-term survival. CA Cancer J Clin 66: 115-129, 2016.

18. Morgan MA, Parsels LA, Parsels JD, Mesiwala AK, Maybaum J and Lawrence TS: Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine. Cancer Res 65: 8382-842, 2005.

19. Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaffit WT, Lin L, Hoog J, Goiffon RJ, Prat A, et al: Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 122: 1541-1552, 2012.

20. Gohde MA, Scuito MR, Alves MV, Pickering CR, Osman AA, Nesmy DK, Zhao M, Fitzgerald AL, Myers JN and Friedman MJ: CHK1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 12: 1860-1873, 2013.

21. Algibis L, Goubar A, Scott Y, Vicier C, Lefèbvre C, Alsafadi S, Commo F, Saghatelian M, Lazar V, Dessel P, et al: CHK1 as a new therapeutic target in triple-negative breast cancer. Breast 23: 250-258, 2014.